drugset / Trial / NCT01714661
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Phase 3
Completed
753 enrolled
FORUM Pharmaceuticals Inc
NeuroCog Trials, Inc. · collabSyneos Health · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine if EVP-6124 (an alpha-7 nAChR agonist) enhances the cognitive abilities of subjects with Schizophrenia who are also taking stable antipsychotic therapy.
Timeline
- Start
- 2012-10
- Primary completion
- 2015-12
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ENCENICLINE | Small molecule | — | Oral |